Fujian Gutian Pharmaceutical Co., Ltd.

This product has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has a bactericidal effect on Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis; it only has an antibacterial effect on anaerobic bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis, etc. Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus are usually resistant to chloramphenicol. Chloramphenicol is fat-soluble and its mechanism of action is to diffuse into bacterial cells and reversibly bind to the 50S subunit of bacterial ribosomes, inhibiting the formation of peptide chains and thus preventing protein synthesis.

Kanamycin sulfate is an aminoglycoside antibiotic. It has good antibacterial effects on most Enterobacteriaceae such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, Citrobacter, Providencia, Yersinia, etc.; influenza bacillus, Brucella, meningococci, gonococci, etc. are also mostly sensitive to this product. Kanamycin also has a certain effect on Staphylococcus (methicillin-sensitive strains) and Mycobacterium tuberculosis, but is ineffective against Pseudomonas aeruginosa. Other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, Enterococcus and anaerobic bacteria are mostly resistant to this product. This product mainly binds to the 30S subunit of the bacterial ribosome and inhibits bacterial protein synthesis. In recent years, the number of resistant strains has increased significantly, because some bacteria produce aminoglycoside inactivating enzymes, which make them lose their antibacterial activity. Kanamycin has complete cross-resistance with streptomycin and neomycin, and may have partial cross-resistance with other aminoglycosides.

This product is an aminoglycoside antibiotic. It has good antibacterial effects on various Gram-negative and Gram-positive bacteria, and has good antibacterial effects on various Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Pseudomonas aeruginosa. Neisseria and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella, Yersinia pestis, Acinetobacter and Campylobacter fetus. It has a good antibacterial effect on about 80% of methicillin-sensitive strains of Staphylococcus (including Staphylococcus aureus and coagulase-negative Staphylococci), but methicillin-resistant strains are mostly resistant to this product. It has a poor effect on Streptococcus and Streptococcus pneumoniae, and Enterococcus is mostly resistant to this product. When this product is used in combination with beta-lactams, most of them can obtain a synergistic antibacterial effect. The mechanism of action of this product is to bind to the 30S subunit of bacterial ribosomes and inhibit the synthesis of bacterial proteins. In recent years, the number of gram-negative bacteria resistant to gentamicin has increased significantly.

This product is an aminoglycoside antibiotic, which has good antibacterial effect on various Gram-negative and Gram-positive bacteria. It has good antibacterial effect on Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Enterobacter, Serratia and Pseudomonas aeruginosa. Neisseria and Haemophilus influenzae are moderately sensitive to this product. It also has a certain effect on Brucella, Yersinia pestis, Acinetobacter and Campylobacter fetus. It has a good antibacterial effect on about 80% of methicillin-sensitive strains of Staphylococcus, but methicillin-resistant strains are mostly resistant to this product. It has a poor effect on Streptococcus and Streptococcus pneumoniae, and Enterococcus is mostly resistant to this product. When this product is used in combination with beta-lactams, most of them can obtain synergistic antibacterial effects. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. In recent years, the number of Gram-negative bacteria resistant to gentamicin has increased significantly.

This product is an aminoglycoside antibiotic. The antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on Gram-negative bacteria such as Escherichia coli, aerogenes, Klebsiella, Proteus mirabilis, some indole-positive Proteus, Pseudomonas aeruginosa, some Neisseria, some non-pigmented Serratia and Shigella. Among Gram-positive bacteria, Staphylococcus aureus (including β-lactamase-producing strains) is sensitive to this product; Streptococci (including Streptococcus pyogenes, Pneumococcus, Streptococcus faecalis, etc.) are resistant to this product. Anaerobic bacteria (Bacteroides), Mycobacterium tuberculosis, Rickettsia, viruses and fungi are also resistant to this product. This product is stable to aminoglycoside acetyltransferase AAC (6') produced by bacteria, so it still has antibacterial activity against bacteria that are resistant to kanamycin, gentamicin, amikacin, ribosomycin, etc. due to the production of this enzyme. The minimum inhibitory concentration of this product is 0.1-6.25 mg/L. The mechanism of action of this product is to bind to the bacterial ribosome 30S subunit and inhibit the synthesis of bacterial protein.